Ivermectin for Covid-19

Discussion of scholarly papers published on Ivermectin, starting from the article of Caly et al. in Antiviral Research, available online April 3, 2020, and of some news that we can find about the use of this drug for the treatment of Covid-19. A list of clinical trials is also given. The proposed discussion was made in a series of versions from 14 June to 29 July 2020. Here updates (September 8, September 20). For what concerns scholarly papers, we report among them three preprints in MedRχiv. One, posted on 10 June, concludes that Ivermectin was associated with lower mortality during treatment of Covid-19. The other preprints, posted on 8 July and 15 September, are showing results of clinical studies. The preprint of July 8 tells, in its conclusions that add-on use of Ivermectin is giving better results when compared to controls, in particular a significant shorter hospitalization. The preprint of September 15 is reporting about the use of ivermectin, dexamethasone, enoxaparin and aspirin in the treatment of Covid-19. A preprint, posted in Research Square on July 14, is reported too. This preprint is giving the result of a trial regarding the combinations Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin. Among news, we consider especially the news regarding the use of Ivermectin in Peru. The case of Iquitos is discussed in detail. Epidemic data in this region are considered. News displaying the observation of rare symptoms of Covid-19, is also reported in detail. The observation was related to a large set of patients in Lima. The updates (8 September 2020 and 20 September 2020) are given in Appendix B and C.